Get started
Hepion Pharmaceuticals, Inc.HH

Hepion Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

HEPA trade ideas

Hepion Pharmaceuticals - an opportunity like no other* cautious investment opportunity - low market capital * 4-years of price action resistance, a 99.96% correction, and now a higher low in price action following the oversold condition (orange column). So many reasons to be bullish on this stock. Let’s go through them. 1) As mentioned above, price action has broken out from 4 years of resistance. Following that breakout the bottoming candle is now offering support, which just so happens to be support on the previous price action resistance trend line. 2) Regular bullish divergence between price action and Stochastic RSI. 3) Volume - together with point (2) volume has been increasing = very bullish. Someone knows something I don’t. 4) No stock splits! It seems incredible a stock that was once traded for 3000 can now be bought today for 2.20. A buy from 1.92 is amazing if you can get it. 1st target: 150 / yes 6000% 2nd target: 558 / 25,000%
NASDAQ:HEPALong
by without_worries
17
HEPA TargetsUsing the golden ratio as a price target, and previous magnitudes, HEPA looks primed for a run up to the $8.95-$9.93 range by EOY. The top line of the broadening formation will likely cause resistance and a chance for a nice pullback opportunity. The volume of this stock has dried up as the short volume has. Positive data has caused massive dorking of the stock price. Also, the lockout period for the warrants exercisable at $2.50 expires this Sunday. This stock was likely held down during the lockout period in order accumulate shares and shake retail investors out, hence the run ups and quick dorks down. It is currently trading at cash value (corporate presentation indicated 115.4m cash as of 3/31/21 and current market cap is 113.56M). Further, the Chief Medical Officer of HEPA, Dr. Hobbs, came over from Norvo Nordisk, a 183.63b company as of this write up, after 16 year there where he was North American Chief Medical Officer and Vice President. Normally, such a move requires a non-compete clause, but Dr. Hobbs transitioned immediately which could indicate there is a collaboration in the works - though that's entirely speculative at this point. The drug CRV431 and the AI Power platform have both shown unmatched early positive results in a field in which there is a giant void to be filled: NASH. There are currently no drugs on the market for NASH, and CRV431 is already proving to be extremely positive in what little results we've been allowed to see. There has been virtually radio silence from the company when it comes to the positive results thus far, which is another oddity similar to Dr. Hobbs. Normally, a company would be screaming from the rooftops how great its results are in order to attract more investors to raise additional capital. Not so here. Again this is all speculative, but it could indicate, along with the suppression of stock price and lockout period, that the price was suppressed in order to accumulate shares before revealing information that would skyrocket the price, and after the lockout period expiration. Technicals looks good, the company has solid leadership, and their products have shown unparalleled results thus far. It's trading at 52 week lows with seller fatigue completely set in with volume dried up. This is great entry point with tremendous upside potential.
NLong
by getreqed
2
HEPA - a good buy opportunity? Very likely for me!First of all, I am not an expert when it comes to pharmaceutical companies! Why did I pick Hepion Pharmaceuticals (@hepionpharma)? 1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1) 2. They came from a super high share price and are currently on a super low level 3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found. CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug. Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest. Take a look at the chart and the health of the company with future prospective - then shape your own opinion. - This is no financial advice, so trade with care!- For transparency reasons: I am invested in $HEPA with 2/10 of my stock account size.
NLong
by RedFoxTrading